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A B S T R A C T
Background: We compared efﬁcacy of bare-metal stent (BMS) and drug-eluting balloon (DEB)
combination vs BMS alone, in patients with non-ST elevation acute coronary syndrome treated with
percutaneous coronary intervention (PCI).
Methods: Patients with non-ST elevation myocardial infarction (NSTEMI) or unstable angina (UA) were
randomized to BMS only or BMS + DEB group. Angiographic follow-up was performed after 6 months.
The primary endpoints were binary in-stent restenosis (ISR) and late lumen loss (LLL) and the secondary
endpoints were target lesion revascularization (TLR), stent thrombosis (ST), and new acute coronary
syndrome (ACS).
Results: A total of 85 patients were enrolled, 44 (BMS) and 41 (BMS + DEB). The median age was 67 (36–
84) years and 68 (80%) were male. Fifty-two patients (61.2%) had NSTEMI and 33 patients (38.8%) UA.
There was no difference in patient demographics, risk factors, and clinical characteristics, except for
more smokers in the BMS + DEB group 18/41 (43.9%) vs 9/44 (20.5%). At follow-up, no signiﬁcant
difference in binary ISR was found; p = 0.593, but LLL was signiﬁcantly lower in the BMS + DEB group
0.68 (0.00–2.15) mm vs 0.22 (0.00–2.35) mm; p = 0.002. The difference in major adverse cardiac events
(MACE) rate combining TLR, ST, and ACS, between the groups was also non-signiﬁcant, 29.5% (BMS) vs
24.4% (BMS + DEB); p = 0.835. One patient had a subacute ST (BMS + DEB) due to clopidogrel resistance.
Conclusion: Patients treated with BMS + DEB combination for non-ST elevation acute coronary
syndrome had signiﬁcantly less LLL in comparison to patients treated with BMS alone but without
an impact on patient clinical outcomes.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Drug-eluting balloons (DEBs) are coated with paclitaxel, a
potent cell inhibitor which irreversibly inhibits arterial smooth
muscle cell proliferation. They can be used in combination with
bare metal stent (BMS) or alone (DEB only). The usage of DEB in
BMS and drug-eluting stent (DES) restenosis showed good clinical
results [1–4] and therefore they have a class IIA, level of evidence B
indication for in-stent restenosis (ISR) in the European guidelines
[5]. Their effect in de novo coronary lesions is controversial and
there are several studies and trials with conﬂicting results in
patients with stable coronary artery disease. Good results are* Corresponding author at: University Hospital Centre Zagreb – KBC Zagreb,
Kispaticeva 12, 10000 Zagreb, Croatia. Tel.: +385 12367508/912336805;
fax: +385 12367512.
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http://dx.doi.org/10.1016/j.jjcc.2014.05.007
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsachieved in small vessel disease, long lesions, and bifurcations
especially without concomitant BMS implantation. There are few
data about DEB in acute coronary syndromes. The only large trial
was the DEB-AMI trial in ST-elevation myocardial infarction
(STEMI) patients [6], but randomized trials in non-ST elevation
coronary syndromes (BMS) are missing. The only data are from
small studies or registers. There are some randomized trials currently
being conducted (DEBUT – DEB vs BMS, DEB ﬁrst – DEB + BMS vs DES,
PEPCADNSTEMI – BMS vs DEB with provisional stenting).
Patients with non-ST elevation myocardial infarction (NSTEMI)
or unstable angina (UA) are usually older then STEMI patients with
more comorbidity and multivessel disease. Complications during
and after percutaneous coronary intervention (PCI) are not rare
and they have a higher incidence of stent thrombosis and
restenosis than patients with stable coronary artery disease. The
purpose of this study was to evaluate the angiographic and clinical
outcomes of BMS + DEB in patients with non-ST elevation acute
coronary syndrome. reserved.
Table 1
Baseline characteristics of the study population.
BMS BMS + DEB
44 patients 41 patients
Age (years) 68 (36–84) 63 (41–79)
Male 35/44 (79.5%) 33/41 (80.5%)
UA 17/44 (38.6%) 16/41 (39.0%)
NSTEMI 27/44 (61.4%) 25/41 (61.0%)
GRACE SCORE 126 (66–176) 131 (60–186)
BMI 28.1 (22.1–37.3) 29.0 (22.0–36.4)
Hypertension 44/44 (100%) 41/41 (100%)
Diabetes mellitus 12/44 (27.3%) 13/41 (31.7%)
Hyperlipidemia 39/44 (88.6%) 36/41 (87.8%)
Smoking 9/44 (20.5%) 18/41 (43.9%)
Chronic kidney disease 3/44 (6.8%) 6/41 (14.6%)
Prior myocardial infarction 6/44 (13.6%) 4/41 (9.8%)
Prior PCI 3/6 (50%) 2/2 (50%)
LVEF (%) 60 (35–74) 60 (35–70)
Values are presented as median and range or number (%).
BMS, bare-metal stent; DEB, drug-eluting balloon; UA, unstable angina;
NSTEMI, non-ST elevation myocardial infarction; GRACE, Global Registry of
Acute Coronary Events score; BMI, body mass index; PCI, percutaneous
coronary intervention; LVEF, left ventricular ejection fraction.
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This is a single-center, randomized, prospective study of
patients with non-ST elevation acute coronary syndrome (NSTEMI
and UA) treated in University Hospital Center Zagreb, Zagreb,
Croatia, from February 2011 to June 2013. The University Hospital
Center Ethics Committee approved the study.
Patients
Patients with NSTEMI or UA with signed informed consent for
coronary angiography and participation in this investigation were
included. The patient exclusion criteria were informed consent not
signed, STEMI, cardiogenic shock, hemorrhagic diathesis or major
bleeding within 2 weeks, and contraindication for dual antiplatelet
therapy. Angiographic inclusion criteria were de novo coronary
lesions and exclusion criteria: ISR and left main disease.
Study procedure
Coronary angiography was performed in all patients in the ﬁrst
48 h. The lesions were classiﬁed according to the American College
of Cardiology/American Heart Association classiﬁcation [7]. The
patients were randomized into two groups: BMS only – PCI of the
target lesion with BMS and BMS + DEB combination – PCI of the
target lesion with BMS followed by post-dilatation with DEB. All
patients received 600 mg of clopidogrel and 300 mg of aspirin with
unfractionated heparin during the procedure. The use of glycopro-
tein (GP) IIb/IIIa inhibitors (eptiﬁbatide) during and after PCI was
optional. Lesion pre-dilatation with plain balloons was also
optional. We used two different DEBs: Elutax (Aachen Resonance
GmbH, Aachen, Germany) and SeQuent Please (B. Braun AG,
Melsungen, Germany). They were inﬂated during 30–45 s at 8–
10 atm and a 1:1 balloon to artery ratio was used. We decided to
implant the BMS ﬁrst and then post-dilate with DEB to avoid
geographic mismatch. All patients received dual antiplatlet
therapy during 12 months according to guidelines for acute
coronary syndromes without ST elevation [8]. Baseline, post-
procedure, and follow-up coronary angiographies were analyzed
by quantitative coronary angiography (QCA). We measured the
reference vessel diameter (RVD), minimal lumen diameter (MLD),
and lesion length before PCI and in-stent MLD after PCI. At follow-
up in-stent MLD, late lumen loss (LLL – difference between the
post-procedural and follow-up MLD), and binary in-stent resteno-
sis (deﬁned as 50% or more at follow-up) were measured. No
patient was lost during the follow-up.
Study endpoints
The primary endpoints of interest were binary ISR and late
lumen loss (LLL) and the secondary endpoints were target lesion
revascularization (TLR), stent thrombosis (ST), and new acute
coronary syndrome at 6 months. Angiographic follow-up was
performed after 6 months, except in ﬁve patients who because of a
new acute coronary syndrome were admitted earlier. The main
reason for TLR at follow-up was binary in-stent restenosis 50% by
QCA.
Statistics
The statistical analysis was performed using software STATA/IC
ver.11.1 (StataCorp LP, College Station, TX, USA). Comparisons
between the two groups were performed using the Mann–Whitney
U test for continuous variables and x2 test or Fisher’s exact test for
categorical variables. The level of statistical signiﬁcance was set at
p = 0.05.Results
Patient demographics
A total of 85 patients were included, 44 in the BMS group and 41
in the BMS + DEB group. The median age was 67 (36–84) years, and
there were 68 (80%) males. Fifty-two patients (61.2%) had NSTEMI
and 33 (38.8%) had UA. There was no signiﬁcant difference in
patient demographics, risk factors, and clinical characteristics
between the two groups [age, sex, body mass index (BMI), NSTEMI
or UA, Global Registry of Acute Coronary Events (GRACE) score,
prior myocardial infarction and revascularization, left ventricular
ejection fraction (LVEF), and risk factors] except there were more
smokers in the BMS + DEB group 18/41 (43.9%) vs 9/44 (20.5%).
Patients’ demographics are shown in Table 1.
Angiographic ﬁndings and procedural characteristics
A total of 23 patients (27.1%) had 1-vessel disease, 38 (44.7%) 2-
vessel disease, and 24 (28.2%) 3-vessel disease. The left anterior
descending artery (LAD) was the most common target vessel in
both groups: BMS 16/44 (36.4%) and BMS + DEB 22/41 (53.7%), and
B1 the most common lesion type: BMS 31/43 (72.1%) and
BMS + DEB 32/41 (78%). There was no difference in median stent
diameter between the two groups: BMS 3.0 (2.5–4.0) mm vs
BMS + DEB 3.0 (2.5–3.5) mm, but there was a difference in median
stent length: BMS 18 (12–26) mm vs BMS + DEB 18 (13–24) mm.
However, the median total stent length was the same: 18 (12–62)
mm in the BMS group and 18 (13–63) mm in the BMS + DEB group.
The median number of DEB implanted per patient was 1 (1–3),
diameter 3 (2.5–3.5) mm, length 24 (17–30) mm. Pre-dilatation of
the target lesion was equal in both groups: BMS 19/44 (20.5%) and
BMS + DEB 16/41 (39%), GP IIb/IIIa inhibitors were used rarely BMS
9/44 (20.5%) vs BMS + DEB 4/41 (9.8%). Procedural success was
achieved in 100% of lesions with thrombolysis in myocardial
infarction 3 ﬂow. Data are presented in Tables 2 and 3.
QCA data and follow-up
There was no signiﬁcant difference between the two groups in
RVD: BMS 3.08 (2.22–4.33) mm vs BMS + DEB 3.01 (3.30–4.05)
mm; lesion length: BMS 15.8 (9.3–45.2) mm vs BMS + DEB 15.7
(9.0–48.5) mm; baseline MLD: BMS 0.99 (0.01–1.77) mm vs
Table 2
Basic angiographic data.
BMS BMS + DEB
44 patients 41 patients
Number of diseased vessels 2 (1–4) 2 (1–3)
Treated vessel
RCA 15/44 (34.1%) 14/41 (34.1%)
LAD 16/44 (36.4%) 22/41 (53.7%)
LCX 6/44 (13.6%) 2/41 (4.9%)
D1 1/44 (2.3%) 0/41 (0%)
OM1 4/44 (9.1%) 1/41 (2.4%)
OM2 1/44 (2.3%) 1/41 (2.4%)
RIM 1/44 (2.3%) 1/41 (2.4%)
Lesion type
A 4/43 (9.3%) 3/41 (7.3%)
B1 31/43 (72.1%) 32/41 (78%)
B2 5/43 (11.6%) 5/41 (12.2%)
C 3/43 (7%) 1/41 (2.4%)
Reference vessel diameter (mm) 3.08 (2.22–4.33) 3.01 (3.30–4.05)
Lesion length (mm) 15.8 (9.3–45.2) 15.7 (9.0–48.5)
MLD before PCI (mm) 0.99 (0.01–1.77) 1.18 (0.25–2.24)
Values are presented as median and range or number (%).
BMS, bare-metal stent; DEB, drug-eluting balloon; RCA, right coronary artery;
LAD, left anterior descending; LCX, left circumﬂex; D1, ﬁrst diagonal; OM1, ﬁrst
obtuse marginal; OM2, second obtuse marginal; RIM, ramus intermedius; MLD,
minimal lumen diameter; PCI, percutaneous coronary intervention.
Table 4
Quantitative coronary angiographic data: immediate results and after 6 months
follow-up.
BMS BMS + DEB p-value
44 patients 41 patients
In-stent MLD post-PCI
(mm)
2.72 (1.66–3.80) 2.65 (2.05–3.64) 0.899
In-stent MLD (mm) at
6 months
2.0 (0.65–2.91) 2.31 (0.3–3.64) 0.015
Binary (50%) in-stent
restenosis
10/44 (22.7%) 7/41 (17.1%) 0.593
% in-stent restenosis 30% (0–99%) 20% (0–100%) 0.007
LLL (mm) 0.68 (0.00–2.15) 0.22 (0.00–2.35) 0.002
TLR 10/44 (22.7%) 8/41 (19.5%) 0.770
ST 0/44 (0%) 1/41 (2.4%) 0.488
ACS 3/44 (6.8%) 2/41 (4.8%) 0.720
MACE 13/44 (29.5%) 11/41 (24.4%) 0.835
Values are presented as median and range or number (%).
BMS, bare-metal stent; DEB, drug-eluting balloon; MLD, minimal lumen
diameter; PCI, percutaneous coronary intervention; LLL, late lumen loss; TLR,
target lesion revascularization; ST, stent thrombosis; ACS, acute coronary
syndrome; MACE, major adverse cardiac events.
Table 3
Procedural characteristics.
BMS BMS + DEB
44 patients 41 patients
Number of stents implanted per patient 1 (1–3) 1 (1–3)
Stent length (mm) 18 (12–26) 18 (13–24)
Stent diameter (mm) 3.0 (2.5–4.0) 3.0 (2.5–3.5)
Total stent length (mm) 18 (12–62) 18 (13–63)
Pre-dilatation 19/44 (43.2%) 16/41 (39.0%)
Glycoprotein IIb/IIIa inhibitors 9/44 (20.5%) 4/41 (9.8%)
DEB
Number of DEB per patient – 1 (1–3)
DEB length (mm) – 24 (17–30)
DEB diameter (mm) – 3 (2.5–3.5)
Total DEB length (mm) – 24 (17–66)
Values are presented as median and range or number (%).
BMS, bare-metal stent; DEB, drug-eluting balloon.
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MLD: BMS 2.72 (1.66–3.80) mm vs BMS + DEB 2.65 (2.05–3.64)
mm. Eighty (94.1%) patients had a follow-up angiography at 6
months and ﬁve (5.9%) patients earlier because of NSTEMI or UA.
The incidence of binary ISR was 10/44 (22.7%) in the BMS group
and 7/41 (17.1%) in the BMS + DEB group. All patients were
revascularized percutaneously except one patient from the
BMS + DEB group who was sent to surgery due to in-stent LAD
occlusion. There was a signiﬁcant difference at 6 months follow-up
between the two groups in in-stent MLD: BMS 2.0 (0.65–2.91) mm
vs BMS + DEB 2.31 (0.3–3.64) mm; p = 0.015 and therefore in LLL:
BMS 0.68 (0.00–2.15) mm vs BMS + DEB 0.22 (0.00–2.35) mm;
p = 0.002, but without a difference in major adverse cardiac events
(MACE) (ST, TLR, and new acute coronary syndrome) 13/44 (29.5%)
BMS vs 11/41 (24.4%) BMS + DEB. The incidence of TLR was 10/44
(22.7%) in the BMS group and 8/41 (19.5%) in the BMS + DEB group.
There was one subacute ST in the BMS + DEB group because of
clopidogrel resistance. No deaths occurred (Table 4).
Discussion
The aim of this prospective study was to evaluate the efﬁcacy of
BMS + DEB combination in patients with non-ST elevation acutecoronary syndrome. DEB trials and studies in stable coronary
artery disease have been published with good angiographic and
clinical results. The results in small vessel disease (PEPCAD I,
BELLO) in comparison to paclitaxel DES are encouraging, especially
without concomitant BMS implantation [9,10]. In bifurcation
lesions the results are also promising (PEPCAD V, DEBUIT) even
with BMS use, nevertheless BMS + DEB in the DEBUIT trial was not
superior to BMS alone [11,12]. However, the results in trials
comparing BMS + DEB and DES (PEPCAD III, OCTOPUS) in de novo
coronary lesions were disappointing [13,14] except if it was a
paclitaxel DES (PEPCAD IV, PEPCAD CTO, LOCAL TAX) [15–17].
Trials in acute coronary syndromes are rare. The only trial with
published results is the DEB-AMI trial comparing DEB + BMS, BMS
and DES (Taxus, Boston Scientiﬁc, Natick, MA, USA) in STEMI
patients [6]. The results showed that DEB + BMS were not superior
to BMS only and that both groups were inferior to DES in terms of
binary restenosis, LLL, and MACE after 6 months.
We can conclude that there is strong evidence of DES (limus)
superiority to BMS + DEB in stable coronary artery disease and
STEMI, but data in NSTEMI and UA are missing (trials being
conducted). In Croatia, because of high prices of DES, patients in
acute coronary syndromes are receiving BMS. DES are used in
speciﬁc indications: BMS in-stent restenosis, diabetic patients with
small vessel disease and long lesions, bifurcations, and left main
disease. Therefore, we conducted this study to evaluate the
potential beneﬁt of BMS + DEB in these patients. There are two
studies in favor of BMS + DEB vs BMS. The ﬁrst is the Local Tax
study comparing Genie (ﬂuid paclitaxel) +BMS, BMS and DES
(Taxus). The results were as follows: LLL 0.61 vs 0.99 vs 0.44;
(p = 0.006 Genie + BMS vs BMS). The cumulative overall rate of
MACE was 13.4% vs 26.8% vs 14.9%, p = 0.078. TLR was 13.4% vs
22.1% vs 13.4%; p = 0.23. Compared with BMS-only patients,
patients randomized to receive a BMS plus local paclitaxel
demonstrated superior angiographic results and showed no
inferiority compared with paclitaxel-eluting stents [17].
The second was the Perfect study comparing [endothelial
progenitor capturing (EPC) stent] + DEB with BMS (EPC stent). This
study showed even better results: LLL 0.34 vs 0.88, total segment
binary restenosis 5.1% vs 23.2% (p = 0.005). TLR rates were 4.8% and
15.5%, respectively (p = 0.05). Total major cardiovascular events
(TLR, non-target vessel MI, and cardiac death) rates were 4.8% and
17.2%, respectively. They concluded that EPC stent implantation
followed by DEB post-dilation demonstrated superior LLL and
markedly reduced restenosis rates with no ST events in either
group [18].
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cantly less LLL in comparison to BMS alone, BMS 0.68 (0.00–2.15)
mm vs BMS + DEB 0.22 (0.00–2.35) mm; p = 0.002 at 6-month
angiographic follow-up, but no signiﬁcant difference in binary ISR
and MACE (TLR, ST, and new acute coronary syndrome). The results
are comparable with DEB results in stable coronary artery disease.
Although the overall TLR rates were relatively high 22.7% BMS vs
19.5% BMS + DEB, the clinically driven TLR rates were 6.8% BMS vs
4.8% BMS + DEB. These data are similar with data from studies
where routine angiographic follow-up increased oculostenotic
revascularization of nonischemic intermediate lesions [19]. One
patient from the DEB + BMS group with three implanted BMS
(lesion length 63 mm) had an asymptomatic in-stent occlusion
with collaterals and was deferred to bypass surgery. There was one
subacute ST in the BMS + DEB group because of clopidogrel
resistance. The dose was doubled and the patient was not excluded
from the study with good angiographic follow-up results.
In this study signiﬁcant reduction in LLL did not translate into
signiﬁcant reduction in binary ISR and TLR. This was also observed
in studies comparing BMS and DES, especially comparing the
efﬁcacy of different DES. The possible explanation is the stability of
LLL due to its direct measurement of narrowing and lack of
inﬂuence of other factors in its calculation, in contrast to the
dependency of TLR rate estimation on RVD. Therefore in-stent LLL
provides a more reliable measure of anti-restenosis propensity
than TLR or binary restenosis rates [20,21].
Nevertheless, despite less LLL, there was no impact on the
clinical outcomes of the patients. This was also noted in most
studies comparing DES and BMS, but PCI procedures had been
predominantly performed on a single vessel, as was the case in our
study. However, data from the Frankfurt multivessel PCI registry
showed that the use of DES vs BMS in stable patients with
multivessel PCI was associated with improved survival [22]. In a
retrospective study with acute coronary syndrome patients and
multivessel disease, a difference was observed between STEMI and
NSTEMI patients in terms of type of revascularization and clinical
outcome. Patients with STEMI had a similar risk of mortality if
treated with DES in comparison to coronary artery bypass graft, but
a higher MACE because of repeat revascularizations, whereas in
NSTEMI patients the MACE and mortality were the same [23].
According to this, patients with non-ST elevation acute coronary
syndrome and multivessel disease can be treated with multivessel
PCI. Therefore, a larger sample size of patients with BMS + DEB
multivessel PCI is needed to evaluate this method in terms of
clinical outcome.
There is also the question of DEB only in patients with non-ST
elevation acute coronary syndrome. The data from clinical trials in
stable coronary artery disease demonstrate superiority in LLL of
DEB only vs BMS + DEB. In the Valentines II trial the MACE at 8
months was 8.7%; TLR was 6.9%, cardiac death and myocardial
infarction were 2%, with LLL of 0.30 mm and a 10.7% binary
restenosis rate [24]. Trials in acute coronary syndromes are needed
to evaluate these results.
Study limitations
This study enrolled a relatively small number of patients with a
small percentage of diabetics (29.4%) and patients with renal
insufﬁciency (10.6%), and those are the patients of special interest
due to higher rates of restenosis and reinterventions. The other
limitation is the usage of two different DEB. The Elutax DEB has no
excipient and a paclitaxel concentration of 2 mg/mm2 while the
SeQuent Please has iopromide as an excipient and a paclitaxel
concentration of 3 mg/mm2. In our study we used Elutax DEB in
31/41 (76%) patients vs SeQuent Please in 10/41 (24%) patients.
There are some data from an observational study in Sweden(report from the SCAAR registry) in patients with stable coronary
artery disease and acute coronary syndromes (NSTEMI and
STEMI) that show that the restenosis rate with Elutax DEB was
12.5% and with SeQuent Please 3.4% [25]. These results suggest
that there is no class effect for DEB. Therefore, we can only
speculate what the results of this study would be if we had used
only SeQuent Please DEB and how it would reﬂect on the
angiographic and clinical outcomes of the patients.
Conclusions
There was signiﬁcantly less LLL in BMS + DEB in comparison to
BMS alone, but without an impact on patient clinical outcomes.
The performance of DEB appears to be between DES and BMS, but
studies with larger sample sizes are needed to evaluate the
potential beneﬁt of BMS + DEB combination in this particular
group of patients. We have also recently started a DEB only study in
patients with acute coronary syndromes with promising immedi-
ate and follow-up results. Nevertheless, until more data from
ongoing studies are attainable, DEB may be considered in patients
with contraindications for DES or if DES are not available.
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